10 June 2021 - TRADING BUY
Shares in the life sciences company Clinigen fell sharply yesterday following a profit warning from the company. The pandemic has reduced demand for Proleukin, a drug used in cancer treatment, due to disruption in the treatment of patients. As a result, the company has reduced guidance for the underlying earnings it expects to report for the year to 30 June 2021 with these now likely to be between £114m and £117m compared with forecasts of £130m. This would represent an outcome some 10% lower than expected but the share price of the company fell over . . .
This content is restricted to members only. We offer three packages from 1 month to a whole year of daily tips, market news and commentary, plus our monthly newsletters.
Registration is quick and simple HERE.
Already a member, log in HERE.
